[1] ARAB JP, ARRESE M, TRAUNER M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease[J]. Annu Rev Pathol, 2018, 13(1): 321. doi: 10.1146/annurev-pathol-020117-043617
[2] MVLLER TD, FINAN B, BLOOM SR, et al. Glucagon-like peptide 1(GLP-1)[J]. Mol Metab, 2019, 30: 72. doi: 10.1016/j.molmet.2019.09.010
[3] LYU J, IMACHI H, FUKUNAGA K, et al. Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes[J]. Mol Metab, 2020, 34: 16. doi: 10.1016/j.molmet.2019.12.015
[4] ZHAO B, QIANG L, JOSEPH J, et al. Mitochondrial dysfunction activates the AMPK signaling and autophagy to promote cell survival[J]. Genes Dis, 2016, 3(1): 82. doi: 10.1016/j.gendis.2015.12.002
[5] WANG H, LIU Y, WANG D, et al. The upstream pathway of mtor-mediated autophagy in liver diseases[J]. Cells, 2019, 8(12): 1597. doi: 10.3390/cells8121597
[6] TONG W, JU L, QIU M, et al. Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway[J]. Hepatol Res, 2016, 46(9): 933. doi: 10.1111/hepr.12634
[7] YAN J, YAO B, KUANG H, et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease[J]. Hepatology, 2019, 69(6): 2414. doi: 10.1002/hep.30320
[8] 中华医学会内分泌学分会, 中华医学会糖尿病学分会. 中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识[J]. 中华内分泌代谢杂志, 2021, 37(7): 589. doi: 10.3760/cma.j.cn311282-20210105-00016
[9] HAZLEHURST JM, WOODS C, MARJOT T, et al. Non-alcoholic fatty liver disease and diabetes[J]. Metabolism, 2016, 65(8): 1096. doi: 10.1016/j.metabol.2016.01.001
[10] NIEDERSEER D, WERNLY S, BACHMAYER S, et al. Diagnosis of non-alcoholic fatty liver disease (NAFLD) is independently associated with cardiovascular risk in a large austrian screening cohort[J]. J Clin Med, 2020, 9(4): 1065. doi: 10.3390/jcm9041065
[11] SU K, YI B, YAO BQ, et al. Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis[J]. Pharmacol Res, 2020, 156: 104778.
[12] RONDINELLI M, ROSSI A, GANDOLFI A, et al. Use of liraglutide in the real world and impact at 36 months on metabolic control, weight, lipid profile, blood pressure, heart rate, and renal function[J]. Clin Ther, 2017, 39(1): 159. doi: 10.1016/j.clinthera.2016.11.001
[13] RUSSELL-JONES D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue[J]. Mol Cell Endocrinol, 2009, 297(1): 137.
[14] TAHER J, BAKER CL, CUIZON C, et al. GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance[J]. Mol Metab, 2014, 3(9): 823. doi: 10.1016/j.molmet.2014.09.005
[15] HAO T, CHEN H, WU S, et al. LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a highfat diet[J]. Mol Med Rep, 2019, 20(1): 701.
[16] 沈敏燕, 胡曦, 朱静, 等. 黄连碱促进肝细胞自噬及胆固醇外流改善脂肪肝的脂质蓄积[J]. 蚌埠医学院学报, 2021, 46(4): 421.
[17] ZHANG E, YIN S, SONG X, et al. Glycycoumarin inhibits hepatocyte lipoapoptosis through activation of autophagy and inhibition of ER stress/GSK-3-mediated mitochondrial pathway[J]. Sci Rep, 2016, 6: 38138.
[18] 张强, 刘勤, 牛春燕. 利拉鲁肽减轻脂毒性肝细胞损伤并促进自噬改善非酒精性脂肪肝[J]. 中华肝脏病杂志, 2021, 29(5): 456.
[19] FANG Y, JI L, ZHU C, et al. Liraglutide alleviates hepatic steatosis by activating the tfeb-regulated autophagy-lysosomal pathway[J]. Front Cell Dev Biol, 2020, 8: 602574.
[20] ALTAMIRANO J, QI Q, CHOUDHRY S, et al. Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease[J]. Transl Gastroenterol Hepatol, 2020, 5: 31.
[21] ZHANG S, MAO Y, FAN X. Inhibition of ghrelin oacyltransferase attenuated lipotoxicity by inducing autophagy via AMPK-mTOR pathway[J]. Drug Design, Develop Ther, 2018, 12(4): 873.
[22] 徐玲, 马红艳, 杨军, 等. 高脂饮食通过p-AMPK/mTOR信号通路下调小鼠肝细胞自噬水平[J]. 基础医学与临床, 2018, 38(1): 37.